Detalhe da pesquisa
1.
Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study.
Br J Haematol
; 201(2): 256-266, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36740991
2.
Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study.
Am J Hematol
; 98(4): 645-657, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36606708
3.
Reduced frequency of cytotoxic CD56dim CD16+ NK cells leads to impaired antibody-dependent degranulation in EBV-positive classical Hodgkin lymphoma.
Cancer Immunol Immunother
; 71(1): 13-24, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33993319
4.
High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline.
Haematologica
; 107(12): 2897-2904, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35638548
5.
Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R-Mini-CYVE) regimen for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma not eligible for intensive chemotherapy.
Eur J Haematol
; 106(4): 574-583, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33512026
6.
High-dose cyclophosphamide for hard-to-treat patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, a phase II result.
Eur J Haematol
; 104(4): 281-290, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31838764
7.
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.
Lancet Oncol
; 20(2): 202-215, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30658935
8.
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.
Blood
; 129(18): 2471-2478, 2017 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28270452
9.
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials.
Invest New Drugs
; 36(1): 62-74, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28597151
10.
Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.
Am J Hematol
; 2018 Jun 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29884994
11.
Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphoma.
Haematologica
; 107(8): 1928-1932, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35320922
12.
Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study.
Haematologica
; 107(7): 1681-1686, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34965701
13.
Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma.
Eur J Nucl Med Mol Imaging
; 44(12): 2018-2024, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28634685
14.
Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 study.
Am J Hematol
; 96(10): E376-E379, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34165816
15.
Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.
Haematologica
; 100(12): 1579-86, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26430172
16.
Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies.
J Neurol Neurosurg Psychiatry
; 91(7): 786-788, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32327451
17.
PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma - Authors' reply.
Lancet Oncol
; 20(4): e190, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30942177
18.
Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma.
J Clin Oncol
; 42(1): 19-25, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37967311
19.
Reply: Interim FDG-PET/CT in primary mediastinal diffuse large B-cell lymphoma: really almost useless procedure?
Eur J Nucl Med Mol Imaging
; 45(5): 884-885, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29453703
20.
[Toxicity of targeted therapies and immunotherapy with checkpointinhibitors in Hodgkin lymphoma]. / Toxicité des thérapies ciblées et de l'immunothérapie par inhibiteurs des points de contrôle dans le lymphome de Hodgkin.
Rev Prat
; 73(6): 641-650, 2023 Jun.
Artigo
em Francês
| MEDLINE | ID: mdl-37458554